DTIL

SEC source: 0001209191-20-002445 · doc4.xml · derivative · entry 3

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,351

Underlying: Common Stock · 17,566 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares on August 11, 2017 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-20-002445 · doc4.xml · nonDerivative · entry 2

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-002445 · doc4.xml · nonDerivative · entry 1

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-061581 · doc4.xml · nonDerivative · entry 2

Heery Christopher · CIK 0001789632 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,485

SEC source: 0001209191-19-061581 · doc4.xml · nonDerivative · entry 1

Heery Christopher · CIK 0001789632 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250

SEC source: 0001209191-19-056253 · doc4.xml · derivative · entry 1

Buehler Kevin · CIK 0001792722 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,776

Underlying: Common Stock · 60,776 shares

Expires 2029-11-08

F1 · derivative.exercise_date: The option vests in 36 substantially equal monthly installments following November 8, 2019, such that the option shall be fully vested on November 8, 2022.

SEC source: 0001209191-19-050706 · doc4.xml · derivative · entry 1

KHAZI FAYAZ · CIK 0001770314 · CEO of Elo Life Systems

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,833

Underlying: Common Stock · 28,833 shares

Expires 2029-09-22

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-050705 · doc4.xml · derivative · entry 1

JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,651

Underlying: Common Stock · 52,651 shares

Expires 2029-09-22

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-050702 · doc4.xml · derivative · entry 1

THOMSON DAVID S. · CIK 0001770315 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,922

Underlying: Common Stock · 30,922 shares

Expires 2029-09-22

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-050701 · doc4.xml · derivative · entry 1

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,818

Underlying: Common Stock · 52,818 shares

Expires 2029-09-22

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-050699 · doc4.xml · derivative · entry 4

KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 262,252

Underlying: Common Stock · 262,252 shares

Expires 2029-09-22

F3 · derivative.exercise_date: The option vests as to 25% of the underlying shares on April 1, 2020 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-050699 · doc4.xml · derivative · entry 3

KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,422

Underlying: Common Stock · 10,000 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested as to 25% of the underlying shares on March 24, 2018 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-050699 · doc4.xml · nonDerivative · entry 1

KANE MATTHEW R. · CIK 0001769887 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,812,427

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-049251 · doc4.xml · derivative · entry 2

JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,246

Underlying: Common Stock · 13,176 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 25% of the underlying shares on March 24, 2018 and vests in equal installments at the end of each successive three-month period over the 36 months following such date.

SEC source: 0001209191-19-049251 · doc4.xml · nonDerivative · entry 1

JANTZ DEREK · CIK 0001769828 · Director · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,858,346

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-041388 · doc4.xml · derivative · entry 1

Scimeca Dario · CIK 0001779581 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,000

Underlying: Common Stock · 160,000 shares

Expires 2029-07-03

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 10, 2020 and as to 6.25% of the underlying shares at the end of each successive three-month period until June 10, 2023.

SEC source: 0001209191-19-036287 · doc4.xml · derivative · entry 4

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,026

Underlying: Common Stock · 7,027 shares

Expires 2027-03-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests as to 25% of the underlying shares on March 24, 2018 and vests in equal installments at the end of each successive three-month period over the following 36 months.

SEC source: 0001209191-19-036287 · doc4.xml · derivative · entry 3

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,917

Underlying: Common Stock · 96,618 shares

Expires 2026-08-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on August 11, 2017 and vests in equal installments at the end of each successive three-month period over the following 36 months.

SEC source: 0001209191-19-036287 · doc4.xml · nonDerivative · entry 2

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,645

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-036287 · doc4.xml · nonDerivative · entry 1

ANSARI ABID · CIK 0001770149 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,618

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-036286 · doc4.xml · derivative · entry 2

THOMSON DAVID S. · CIK 0001770315 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,113

Underlying: Common Stock · 117,113 shares

Expires 2027-06-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on May 31, 2018 and vests in equal installments at the end of each successive three-month period over the following 36 months.

SEC source: 0001209191-19-036286 · doc4.xml · nonDerivative · entry 1

THOMSON DAVID S. · CIK 0001770315 · Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,113

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-023673 · doc4.xml · nonDerivative · entry 1

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By ArrowMark Life Science Fund, LP

Disclosed balance after: 158,003

F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $15.28 to $15.50, inclusive. The reporting person undertakes to provide to Precision BioSciences, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1).

F2 · ownership.nature: These securities are held of record by the ArrowMark Life Science Fund, LP (the "ArrowMark Fund"). ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001012975-19-000254 · edgar.xml · derivative · entry 5

venBio Global Strategic Fund, L.P. · CIK 0001504130 · Director · 10% owner

venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner

venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner

Adelman Robert J · CIK 0001329161 · Director · 10% owner

GOODMAN COREY S · CIK 0001278411 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 467,518 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F2 · ownership.nature: venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.

SEC source: 0001012975-19-000254 · edgar.xml · derivative · entry 4

venBio Global Strategic Fund, L.P. · CIK 0001504130 · Director · 10% owner

venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner

venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner

Adelman Robert J · CIK 0001329161 · Director · 10% owner

GOODMAN COREY S · CIK 0001278411 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,747,623 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F1 · derivative.exercise_date: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F1 · derivative.expiration_date: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F2 · ownership.nature: venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.

SEC source: 0001012975-19-000254 · edgar.xml · nonDerivative · entry 3

venBio Global Strategic Fund, L.P. · CIK 0001504130 · Director · 10% owner

venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner

venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner

Adelman Robert J · CIK 0001329161 · Director · 10% owner

GOODMAN COREY S · CIK 0001278411 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,265,141

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F2 · ownership.nature: venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.

SEC source: 0001012975-19-000254 · edgar.xml · nonDerivative · entry 2

venBio Global Strategic Fund, L.P. · CIK 0001504130 · Director · 10% owner

venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner

venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner

Adelman Robert J · CIK 0001329161 · Director · 10% owner

GOODMAN COREY S · CIK 0001278411 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 3,797,623

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each share of the Issuer's preferred stock converted into shares of the Issuer's common stock, $0.000005 par value per share, on a one-for-2.134686 basis upon the closing of the Issuer's initial public offering, after giving effect to the reverse stock split effected by the Issuer in connection with the initial public offering.

F2 · ownership.nature: venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.

SEC source: 0001012975-19-000254 · edgar.xml · nonDerivative · entry 1

venBio Global Strategic Fund, L.P. · CIK 0001504130 · Director · 10% owner

venBio Global Strategic GP, L.P. · CIK 0001770834 · 10% owner

venBio Global Strategic GP, Ltd. · CIK 0001770835 · 10% owner

Adelman Robert J · CIK 0001329161 · Director · 10% owner

GOODMAN COREY S · CIK 0001278411 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 50,000

F2 · ownership.nature: venBio Global Strategic GP, LP is the sole general partner of venBio Global Strategic Fund, LP and venBio Global Strategic GP, Ltd. is the sole general partner of venBio Global Strategic GP, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · derivative · entry 8

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By THB Iron Rose, LLC Life Science Portfolio

Disclosed balance after: 0

Underlying: Common Stock · 4,450 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · derivative.exercise_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · derivative.expiration_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F3 · ownership.nature: These securities are held of record by the THB Iron Rose, LLC Life Science Portfolio (the "THB Fund"). ArrowMark Colorado is an investment advisor to the THB Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the THB Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · derivative · entry 7

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By ArrowMark Life Science Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 114,570 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · derivative.exercise_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · derivative.expiration_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F2 · ownership.nature: These securities are held of record by the ArrowMark Life Science Fund, LP (the "ArrowMark Fund"). ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · derivative · entry 6

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By ArrowMark Life Science Fund, LP

Disclosed balance after: 0

Underlying: Common Stock · 36,946 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

F4 · derivative.exercise_date: On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

F4 · derivative.expiration_date: On March 1, 2019, the ArrowMark Fund acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

F2 · ownership.nature: These securities are held of record by the ArrowMark Life Science Fund, LP (the "ArrowMark Fund"). ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · derivative · entry 5

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,450 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · derivative.exercise_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · derivative.expiration_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

SEC source: 0001209191-19-022659 · doc4.xml · nonDerivative · entry 4

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By THB Iron Rose, LLC Life Science Portfolio

Disclosed balance after: 4,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F3 · ownership.nature: These securities are held of record by the THB Iron Rose, LLC Life Science Portfolio (the "THB Fund"). ArrowMark Colorado is an investment advisor to the THB Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the THB Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · nonDerivative · entry 3

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By ArrowMark Life Science Fund, LP

Disclosed balance after: 151,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F2 · ownership.nature: These securities are held of record by the ArrowMark Life Science Fund, LP (the "ArrowMark Fund"). ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · nonDerivative · entry 2

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By ArrowMark Life Science Fund, LP

Disclosed balance after: 36,946

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: These securities are held of record by the ArrowMark Life Science Fund, LP (the "ArrowMark Fund"). ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022659 · doc4.xml · nonDerivative · entry 1

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

SEC source: 0001209191-19-022658 · doc4.xml · derivative · entry 4

Schinazi Raymond F · CIK 0001397607 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By RFS Partners, LP

Disclosed balance after: 0

Underlying: Common Stock · 56,102 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F2 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F2 · derivative.exercise_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F2 · derivative.expiration_date: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022658 · doc4.xml · derivative · entry 3

Schinazi Raymond F · CIK 0001397607 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By RFS Partners, LP

Disclosed balance after: 0

Underlying: Common Stock · 36,946 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

F3 · derivative.exercise_date: On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

F3 · derivative.expiration_date: On March 1, 2019, RFS acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from the Issuer. Effective upon the closing of the IPO on April 1, 2019, the 2019 Note, including accrued interest, converted into 36,946 shares of the Issuer's common stock at a price per share equal to $13.60, which represented 85% of the price per share in the IPO.

F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022658 · doc4.xml · nonDerivative · entry 2

Schinazi Raymond F · CIK 0001397607 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By RFS Partners, LP

Disclosed balance after: 93,048

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series B Preferred Stock automatically converted into the common stock of Precision BioSciences, Inc. (the "Issuer") on a 2.134686-to-1 basis (after giving effect to the Issuer's previously completed reverse stock split) upon the closing of the Issuer's initial public offering (the "IPO").

F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-022658 · doc4.xml · nonDerivative · entry 1

Schinazi Raymond F · CIK 0001397607 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By RFS Partners, LP

Disclosed balance after: 36,946

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The securities reported herein are held of record by RFS Partners LP ("RFS"). RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the securities held by RFS, except to the extent of any pecuniary interest therein.

SEC source: 0000315066-19-001467 · primary_doc.xml · derivative · entry 5

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · By F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 0

Underlying: Common Stock · 409,078 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

F1 · price: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

F1 · derivative.exercise_date: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

F1 · derivative.expiration_date: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

SEC source: 0000315066-19-001467 · primary_doc.xml · derivative · entry 4

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · By F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 0

Underlying: Common Stock · 3,279,170 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

F1 · price: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

F1 · derivative.exercise_date: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

F1 · derivative.expiration_date: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

SEC source: 0000315066-19-001467 · primary_doc.xml · nonDerivative · entry 3

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · By F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 3,738,248

SEC source: 0000315066-19-001467 · primary_doc.xml · nonDerivative · entry 2

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · By F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 3,688,248

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

SEC source: 0000315066-19-001467 · primary_doc.xml · nonDerivative · entry 1

FMR LLC · CIK 0000315066 · See Remark 1

10b5-1 filing: Not disclosed

Ownership: Indirect · By F-Prime Capital Partners Healthcare Fund IV LP

Disclosed balance after: 3,279,170

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.

SEC source: 0001209191-19-021849 · doc4.xml · derivative · entry 1

YAO TONY DUNG LING · CIK 0001771680 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By ArrowMark Life Science Fund, LP

Disclosed balance after: Not disclosed

Underlying: Common Stock · 36,946 shares

Expires not disclosed

F1 · kind: On March 1, 2019, ArrowMark Life Science Fund, LP (the "ArrowMark Fund") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F1 · derivative.exercise_date: On March 1, 2019, ArrowMark Life Science Fund, LP (the "ArrowMark Fund") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F1 · derivative.expiration_date: On March 1, 2019, ArrowMark Life Science Fund, LP (the "ArrowMark Fund") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F2 · ownership.nature: The 2019 Note is held of record by the ArrowMark Fund. ArrowMark Colorado Holdings LLC ("ArrowMark Colorado") is an investment advisor to the ArrowMark Fund. The reporting person is employed as a portfolio manager for ArrowMark Colorado and has direct voting and dispositive control over the shares held by the ArrowMark Fund. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-021848 · doc4.xml · derivative · entry 2

Schinazi Raymond F · CIK 0001397607 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By RFS Partners, LP

Disclosed balance after: Not disclosed

Underlying: Common Stock · 36,946 shares

Expires not disclosed

F2 · kind: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F2 · derivative.exercise_date: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F2 · derivative.expiration_date: On March 1, 2019, RFS Partners LP ("RFS") acquired a convertible promissory note in the principal amount of $500,000 (the "2019 Note") from Precision BioSciences, Inc. (the "Issuer"). In connection with the pricing of the Issuer's initial public offering on March 27, 2019 (the "IPO"), the conversion price of the 2019 Note became fixed at 85% of the price per share in the IPO, and the 2019 Note became automatically convertible into shares of the Issuer's common stock at the closing of the IPO.

F3 · ownership.nature: The 2019 Note is held of record by RFS. RFS & Associates, LLC ("RFS & Associates") is the general partner of RFS, and the reporting person is a limited partner of RFS as well as the manager of RFS & Associates. The reporting person disclaims beneficial ownership of the 2019 Note, except to the extent of any pecuniary interest therein.

SEC source: 0001209191-19-021848 · doc4.xml · derivative · entry 1

Schinazi Raymond F · CIK 0001397607 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,544

Underlying: Common Stock · 34,544 shares

Expires 2029-03-26

F1 · derivative.exercise_date: The option vests as to 34% of the underlying shares on March 27, 2020 and vests in equal installments at the end of each successive three-month period over the following 24 months.